TIRZEPATIDE

Summary

Tirzepatide is one of the most potent research peptides in the metabolic and weight management field: it is being studied for its role in appetite, blood sugar, and weight loss. Technically, it is a 39-amino acid peptide that acts as a dual GIP and GLP-1 receptor agonist (LY-3437943), the benchmark for the latest generation of incretins.

What is it researched for?

• •  Glucose control and insulin sensitivity
• •  Appetite and satiety regulation
• •  Body weight reduction and body composition
• •  Cardiometabolic markers

Cycle and Rest

Mechanism of Action

Dual Incretin Agonism (GIP / GLP-1)

It combines the activation of the GLP-1 receptor (satiety and insulin secretion) with that of the GIP receptor (insulin sensitivity and lipid management), with a synergistic effect on glycemic control and weight.

Weight reduction and glycemic control

The sum of both mechanisms produces one of the most pronounced effects on body weight observed in clinical research.

Cardiometabolic outcomes

Its impact on blood pressure, lipid profile, and other cardiometabolic markers is being investigated.

Scientific Evidence

Dual agonism (GIP/GLP-1): Receptor studies confirm a balanced agonism, which is the basis of its metabolic potency.

Weight and Glycemia: In the SURMOUNT-1 Phase 3 trial (NEJM, 2022), tirzepatide achieved weight reductions of up to ~20.9% at 72 weeks.

Cardiometabolic: Clinical programs describe consistent improvements in metabolic parameters.

Product Use

Due to its dual mechanism and outstanding clinical results, Tirzepatide is a top-tier reference material in metabolic and weight control research. At Peptido BioGenetic, we supply it as a high-purity peptide for laboratory use, with a certificate of analysis (COA) available upon request.

⚠️ Product exclusively for research and laboratory use. Not suitable for human or veterinary consumption.